Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01SXY
|
|||
| Former ID |
DIB001715
|
|||
| Drug Name |
NVB-302
|
|||
| Synonyms |
Nov-207; Lantibiotic-based protein (C difficile infection), Novacta
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | C. difficile infection [ICD-11: 1A04; ICD-10: A00-B99] | Phase 1 | [1] | |
| Clostridium infection [ICD-11: 1A04; ICD-10: A04.7] | Phase 1 | [2] | ||
| Company |
Novacta Biosystems Ltd
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020 May;19(5):311-332. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030483) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.